SR One
North America, Massachusetts, United States, Cambridge
Description
SR One is the corporate venture capital arm of GlaxoSmithKline.
Investor Profile
SR One has made 193 investments, with 10 in the past 12 months and 30% as lead.
Stage Focus
- Series B (27%)
- Series A (25%)
- Series C (19%)
- Series D (8%)
- Series Unknown (8%)
- Post Ipo Equity (4%)
- Series E (3%)
- Seed (2%)
- Private Equity (2%)
- Series F (1%)
Country Focus
- United States (75%)
- United Kingdom (15%)
'%3e%3cpath fill='%23012169' d='M0 0v30h60V0z'/%3e%3cpath stroke='%23fff' stroke-width='6' d='m0 0 60 30m0-30L0 30'/%3e%3cpath stroke='%23C8102E' stroke-width='4' d='m0 0 60 30m0-30L0 30' clip-path='url(%23b)'/%3e%3cpath stroke='%23fff' stroke-width='10' d='M30 0v30M0 15h60'/%3e%3cpath stroke='%23C8102E' stroke-width='6' d='M30 0v30M0 15h60'/%3e%3c/g%3e%3c/svg%3e)
- Canada (3%)
- Switzerland (2%)
- Denmark (2%)
- Israel (1%)
- The Netherlands (1%)
- Japan (1%)
- Norway (1%)
- Belgium (1%)
Industry Focus
- Biotechnology
- Health Care
- Therapeutics
- Medical
- Pharmaceutical
- Life Science
- Biopharma
- Medical Device
- Health Diagnostics
- Oncology
FAQ
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
